Human embryonic stem cells (hESC) can self-renew indefinitely in vitro, and with the appropriate cues can be induced to differentiate into potentially all somatic cell lineages. Differentiated hESC derivatives can potentially be used in transplantation therapies to treat a variety of celldegenerative diseases. However, hESC differentiation protocols usually yield a mixture of differentiated target and off-target cell types as well as residual undifferentiated cells. For the translation of differentiated hESC-derivatives from the laboratory to the clinic, it is important to be able to discriminate between undifferentiated (pluripotent) and differentiated cells, and generate methods to separate these populations. Safe application of hESC-derived somatic cell types can only be accomplished with pluripotent stem cell-free populations, as residual hESCs could induce tumors known as teratomas following transplantation. Towards this end, here we describe a methodology to detect pluripotency associated cell surface antigens with the monoclonal antibodies TG30 (CD9) and GCTM-2 via fluorescence activated cell sorting (FACS) for the identification of pluripotent TG30 Hi -GCTM-2
Introduction
HPSC (hPSC) include human embryonic stem cells (hESC) and human induced pluripotent stem cells (hIPSC). HPSC can self-renew indefinitely in appropriate culture conditions without losing their ability known as "pluripotency". Pluripotency is defined as the potential for a cell to differentiate into essentially any somatic cell lineage including cells representative of each of the three embryonic germ cell layers. The remarkable potential of hPSC provides a means for a large variety of cell-based applications including therapeutic options. For instance, there are disorders involving cell death and degeneration, where normal functionality of cells in the human body is compromised, as in heart failure, spinal injuries, diabetes, Parkinson's disease, some cancers, and other clinical pathologies. Patients suffering these conditions could potentially be treated by transplanting healthy and functional somatic cells that have been derived from hPSC in the laboratory. However, the current hPSC differentiation protocols are not 100% efficient and yield a mixture of differentiated target and off-target cell types, as well as residual hPSCs that have not undergone differentiation, instead continuing to self-renew [1] [2] [3] . The presence of even a small number of hPSC in a sample of hPSC-derived somatic cells intended for transplantation into patients constitutes a serious clinical risk as these cells by their inherent nature to form tissues of all three embryonic germ layers, could potentially form in vivo a type of tumor known as a teratoma. Therefore, only target cell populations determined to be free of pluripotent stem cells can be considered safe for transplantation into patients. There are several approaches reported to potentially accomplish the purging of residual hPSCs following differentiation, (for review see Polanco and Laslett 4 ). We have previously reported the use of the monoclonal antibodies TG30 (CD9) and GCTM-2 coupled to fluorescence activated cell sorting (FACS) to identify pluripotent stem cells and discriminate them from cells undergoing early stage of differentiation in cultures of hESC lines [5] [6] [7] .
One advantage of using antibodies to detect cell surface antigens is that the target cells are usually viable after antibody binding and/or labeling. Therefore, target cells can be collected after antibody labeling and recultured for expansion and further applications before transplantation. One caveat for cell surface antigens expressed on hPSC is that they are not exclusive to the pluripotent stage and are in many cases re-expressed temporally during development and will therefore be detected in some differentiated cell types. Therefore, if the aim is to use antibodies to detect human pluripotent cells and purge them from a sample of hPSC-derived cells, selected antibodies should not also react with antigens on the specific differentiated cell types intended for transplantation. Unfortunately, there are limited numbers of antibodies that detect cell surface markers on live hPSCs surface marker is not sufficient to eliminate all hPSC, suggesting that any attempt to eliminate all hPSC pluripotent subpopulations should rely on methods that use two or more antibodies detecting different epitopes expressed by hPSCs [9] [10] . As mentioned above, only hPSC-derived cells that could be determined as pluripotent stem cell-free cell populations are appropriate for human transplantation. Reaching this level of stringency may not be achieved with a single pass through an antibody-mediated cell sorting technology. Reculture of the enriched population of differentiated target cells and subsequent rounds of cell sorting may be required to definitively obtain pluripotent stem cell-free samples.
In our laboratory, we have extensively characterized two hES cell-surface antibodies, TG30 (CD9) and GCTM-2, for the detection of live pluripotent cells. Our studies have shown that combined detection of both TG30 and GCTM-2 strongly correlates with the expression of canonical pluripotency-associated genes in hESC lines [5] [6] [7] . TG30/GCTM-2 FACS immunoprofiling has consistently shown that hESC cultures constitute a quantitative continuous gradient of TG30/GCTM-2 expression [5] [6] [7] . We have arbitrarily established four populations (P) of cells within this TG30/GCTM-2 gradient: P4 (TG30 [5] [6] [7] . Our characterization of these P4, P5, P6 and P7 cell populations has shown that the P6 and P7 subfractions express a large number of pluripotencyassociated genes and efficiently form stem-like colonies when recultured post-FACS [2] [3] . On the other hand, P4 (TG30 Neg -GCTM-2 Neg ) cells express a large number of differentiation markers and constitute the spontaneously differentiated cell types that typically occur in expanding cultures of hESC lines [5] [6] . We decided to test the potentiality of our TG30/GCTM-2 FACS for the selective elimination of residual hPSCs following early stage differentiation, and also for the enrichment of pluripotent stem cell populations. The protocol described below shows how to collect and reculture differentiated P4 (TG30 
Protocol
The following protocol was performed using hESC-MEL1 11 
Note: We routinely use MEFs that were mitotically inactivated by γ-irradiation. A protocol for preparation of γ-irradiated MEFs can be found in Michalska
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6. Incubate irradiated MEF cultures at 37 °C/5% CO 2 overnight. The 1/3 flasks can be incubated for 1-4 days without MEF-medium change. These flasks are used for replating of post-FACS cells (as in protocol 4). Full MEF flasks are incubated overnight to generate CM as per below in step 1.2.
DAY -1: Preparation of MEF-conditioned medium (CM)
1. Aspirate MEF-medium from full-MEF T75 flasks. 2. Add pre-equilibrated 25 ml hESC/KOSR medium supplemented with 5 ng/ml human FGF-2 per T75 flask. Incubate at 37 °C/5% CO 2 for 24 hr. 3. Collect MEF-conditioned medium (CM) into a sterile tissue culture tube, freshly supplement CM with 10 ng/ml human FGF-2 and filter using a 0.22 μm polyethersulfone filter. 4. To produce additional CM, repeat steps 1.2.2 and 1.2.3 daily on the same MEF culture for one week.
On the day of performing a TG30/GCTM-2 assay, replace MEF-medium in 1/3 MEF T75 flasks with CM and pre-equilibrate for at least 30 min prior to seeding any hESCs or hESC-derivative cells recovered from the procedure as described below. CM is either used fresh or stored at 4 °C for up to 2 weeks. CM is used in this protocol as in our hands it increases the viability of the cells post-FACS compared to nonconditioned media (results not shown).
2. Rinse the cells in each T75 with 10 ml DPBS and aspirate to remove. 3. Add 3 ml TrypLE Express dissociation solution into each T75 flask. Incubate at 37 °C/5% CO 2 for 5 min. 4. Bump the side of the flasks to obtain complete dislodgement of the cells. Check under microscope. If cells do not dislodge easily, incubate for a further 2-3 min at 37 °C/5% CO 2 . 5. Add 10 ml 20% FBS/DMEM-F12 (kept at 4 °C) to each T75 flask. Using a sterile 10 ml pipette gently triturate the dissociated cells several times against the flask wall to achieve a predominantly single cell suspension. 6. Place a 70 μm cell strainer on a 50 ml sterile polypropylene tube. Use a sterile 10 ml pipette to force the hESC single cell suspensions pooled from the two T75 flasks through the strainer. 7. Discard cell strainer, replace the tube lid and centrifuge the pooled hESC suspension at 1,000 x g for 2 min. 8. Discard supernatant and wash the cells by gently resuspending the pellet in 10 ml 20% FBS/DMEM-F12 (prechilled at 4 °C). 9. Perform a second centrifugation at 1,000 x g for 2 min. 10. Discard supernatant, add 10 ml 20% FBS/DMEM-F12 (prechilled at 4 °C) and gently triturate to resuspend cells. Place the 50 ml tube on ice.
This tube will be used for the Sort Sample immunostaining procedure described below. 11. Take 20 μl of the hESC single cell suspension (step 2.10) for cell number counting using a hemotocytometer. You should expect a yield of 10-15 million cells per T75 flask.
Note: FBS is used in this part of the protocol to increase cell viability post-FACS.
Immunofluorescent Staining of Cell Surface Antigens TG30 and GCTM-2
1. Aliquot 150 μl (~100,000 cells) of a hESC single cell suspension (from step 2.11) into each of six microcentrifuge tubes of 1.5 ml. These six aliquots will be used for the staining controls required to calibrate the assay on the FACS machine. The remaining ~9 ml cell suspension will be your Sort Sample in which the dissociated culture will be costained for detection of TG30 and GCTM-2, according to Tables 1 and 2 Previous reports have established that in hESC standard cultures a mixture of subpopulations coexist exhibiting an expression gradient of genes associated with pluripotency 5, 6, 13 . Combined detection of cell surface antigens like TG30 (CD9) and GCTM-2 allows for the discrimination of a number of subsets of cells at the pluripotent stage and at various stages of early differentiation, as indicated by their expression of stem cell markers and lineage specific transcription factors 5, 6, 13 . In agreement with previous reports, we were able to discriminate P4 (TG30 
Discussion
In the clinical context, differentiated somatic cell types are the final desired product for transplantation and therapeutic applications, and hPSC are a self-renewing and scalable source to generate those somatic cells or their progenitors in the laboratory. The presence of residual undifferentiated hESCs with an inherent potential for teratoma formation is a safety risk when considering hESC-derived somatic cells for transplantation into patients. For a review of this and other risks associated with cell therapy please see Sharpe et al. 16 Therefore, to realize such applications, it is imperative that researchers aim to generate target cell populations that are also pluripotent stem cell-free. Towards this end, we demonstrate here that using our TG30/GCTM-2 FACS methodology it is possible to monitor for the presence of pluripotent cells (TG30 Hi -GCTM-2 Hi ) in a differentiating cell population and obtain viable hESC-differentiated derivatives that can be enriched and recultured post-FACS. Although it is not possible to obtain 100% pluripotent stem cell-free samples with a single pass of our protocol, enriched hESC-derivatives can be recultured and after consecutive passaging 100% somatic-cell purity is achieved. The demonstrated viability of somatic cells for expansion post-FACS also potentially allows for the production of adequate numbers of cells suitable for potential transplantation therapies.
The encouraging results of this pilot study prompted us to perform a more comprehensive investigation using our TG30/GCTM-2 protocol in a comparative study with several human induced pluripotent stem cell (hiPSC) lines 15 . In that study, we found that pluripotent stem cell-free samples obtained using our TG30/GCTM-2 FACS protocol did not generate teratomas when transplanted into immune-deprived mice. Therefore, we can confidently state that with the use of this in vitro protocol, early stage differentiation cell cultures determined to be free of pluripotent TG30 Hi -GCTM-2
Hi cells do not develop teratomas in vivo. This strongly supports the robustness of our assay, providing a potential approach to eliminate the risk of teratoma formation prior to use of hPSC-derived cells in clinical applications.
Conversely, we also show that the TG30/GCTM-2 FACS assay can be used to retrieve a pluripotent cell population with high level of expression of these two surface antigens (TG30 . We therefore reason that the pluripotency network is activated at its maximum levels in TG30 Hi -GCTM-2
Hi expressing cells. We consider that using our TG30/GCTM-2 FACS protocol and retrieving P7 (TG30 Hi -GCTM-2 Hi ) cells could allow for large-scale purification of enriched live hESC cultures, as inputs to differentiation assays.
In conclusion, we demonstrate here the potentiality of our FACS assays based on the combined expression of surface antigens TG30 and GCTM-2 for both the purging and enrichment of hESCs. Future studies with protocols for directed differentiation of hPSCs are likely to also be informative regarding this potentiality. We are aware that in some assays where differentiated hESC-derivatives temporally express TG30 (CD9) or GCTM-2, these two antibodies might not be appropriate or sufficient to purge pluripotent cells from a differentiated population at a particular time point in the assay 6 . Therefore, there is an ongoing need to find novel antibodies that specifically recognize live hESCs to overcome the possible limitation of cross-reaction with some differentiated cell types.
